Physician profile
Anna Boecker
NPI 1912970187
$4,486.12
in general payments reported to CMS, 2019-2025
42 companies · $591 in 2025
The $591 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $482 · 2021: $901 · 2022: $655 · 2023: $448 · 2024: $777 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $646.50 | 2019-2024 | Trintellix |
| Corium, LLC | $361.12 | 2021-2025 | Azstarys |
| Novo Nordisk INC | $348.61 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $345.15 | 2020-2025 | Mounjaro |
| Amarin Pharma, INC. | $289.68 | 2019-2022 | |
| Pfizer INC. | $266.27 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $227.76 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Astrazeneca Pharmaceuticals Lp | $175.57 | 2019-2024 | Airsupra, Farxiga |
| Sanofi Pasteur INC. | $162.64 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $138.44 | 2021-2023 | Qelbree |
| Abbvie INC. | $133.33 | 2021-2025 | |
| Tris Pharma INC | $131.98 | 2019-2025 | Dyanavel Xr |
| Genentech USA, INC. | $119.19 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $103.55 | 2022 | |
| Alk-Abello, INC | $90.77 | 2024 | Grastek, Ragwitek, Odactra |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Boecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.